Search clinical trials for: MK-2214

Total 1878 results

Chinese University of Hong Kong

Completed

MK-2206 in Recurrent Nasopharyngeal Carcinoma (MC1079)

Recurrent Nasopharyngeal Carcinoma

Hong Kong
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; University... and other collaborators

Withdrawn

MK-2206 for Recurrent Malignant Glioma

Malignant Glioma

United States
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Renal Insufficiency
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom, South Africa
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder | MDD

United States, Puerto Rico
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Major Depressive Disorder

Croatia, Brazil, Bulgaria, France, Poland, Russian Federation, South Africa, Hungary, Romania, Ukraine, Argentina, Chile, Slovakia, Colombia, Germany, Serbia, Spain
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Carcinoma, Renal Cell

Spain, United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, United Kingdom
Stanford University
Celgene Corporation

Recruiting

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Leukemia | Leukemia, Myeloid | Monocytic Leukemia

United States
Merck Sharp & Dohme LLC

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (MOONBEAM)

Pulmonary Arterial Hypertension

Germany, United States, Poland, Spain, Colombia, France, Turkey, Israel, Australia, United Kingdom, Netherlands, South Africa
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Kidney Failure, Chronic | Renal Dialysis

United States
Merck Sharp & Dohme LLC

Completed

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Dermatitis, Atopic

United States, Belgium, Bulgaria, Canada, Romania, Spain
Merck Sharp & Dohme LLC

Completed

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Kidney Failure, Chronic | End-Stage Renal Disease | End-Stage Kidney Disease

United States
Yale University

Terminated

FAAH Availability in Psychiatric Disorders: A PET Study

Post Traumatic Stress Disorder | Psychosis | Alcohol Use Disorder

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

Atopic Dermatitis
Merck Sharp & Dohme LLC

Terminated

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

Pharmacokinetics
Merck Sharp & Dohme LLC

Completed

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Hepatic Insufficiency
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)

Alzheimer's Disease
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

Treatment Study for Cognitive Deficits in Schizophrenia (TURNS)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Respiratory Syncytial Virus | Respiratory Tract Infection

United States, Chile, Colombia, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Chronic Cough

United States, Argentina, Colombia, Germany, Guatemala, Israel, Korea, Republic of, Peru, Russian Federation, Spain, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

Chronic Cough

Colombia, Guatemala, Korea, Republic of, Peru, Ukraine, United Kingdom, United States, Canada, Germany, Poland, Russian Federation, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Obstructive Sleep Apnea (OSA)

United States, Belgium
Merck Sharp & Dohme LLC

Terminated

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Acute Cough

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D)
Merck Sharp & Dohme LLC

Terminated

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Type 2 Diabetes
Maastricht University Medical Center

Completed

Comparative Study Menaquinone-7

Bioavailability

Netherlands
Merck Sharp & Dohme LLC

Completed

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I)

Clostridium Difficile Infection
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Hypertension
Merck Sharp & Dohme LLC

Recruiting

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Narcolepsy

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Systemic Lupus Erythematosus

Colombia, United States, Canada, Japan, Chile, France, Poland, Spain, Guatemala, Italy, Malaysia, China
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
Merck Sharp & Dohme LLC

Completed

MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Pulmonary Hypertension

United States, Israel, Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

Alzheimer's Disease
National Human Genome Research Institute (NHGRI)

Completed

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

Proteus Syndrome

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Withdrawn

MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Pneumonia | Coronavirus Disease 2019 (COVID-19) | Hypoxemia
Merck Sharp & Dohme LLC

Completed

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

Postherpetic Neuralgia

Search clinical trials for: MK-2214

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations